non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

• Pathological response and tumor regression grading following neoadjuvant chemo-immunotherapy and chemotherapy in resectable non-small cell lung cancer.#269552NCBI PubMed Central
• Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer#311126ClinicalTrials.gov
• Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation#312111HAL (France)
• A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC#435737ClinicalTrials.gov
• Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC#444878ClinicalTrials.gov
• Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.#683087ClinicalTrials.gov
• Perioperative ΔNLR and ΔPNI independently predict postoperative pulmonary complications in non-small cell lung cancer: a difference analysis-based nomogram.#685576NCBI PubMed Central
• Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients#801866ClinicalTrials.gov
• Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II#829353ClinicalTrials.gov
• Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer#832663ClinicalTrials.gov
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors#300272ClinicalTrials.gov
• Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.#172291ClinicalTrials.gov
• A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION#471463ClinicalTrials.gov
• Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy#839928ClinicalTrials.gov
• Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges#178213HAL (France)
• A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung#18581ClinicalTrials.gov
• Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study#837248ClinicalTrials.gov
• Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy#249588ClinicalTrials.gov
• A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects in vitro and in vivo with paclitaxel against human non-small cell lung cancer#619182bioRxiv / medRxiv
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors#332761ClinicalTrials.gov
• Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer#176518Springer Nature OA
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies#803666ClinicalTrials.gov
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors#842594ClinicalTrials.gov
• Artificial intelligence and machine learning in non-small cell lung cancer: the current state of the science on multi-omic applications.#25830NCBI PubMed Central
• Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC#148774ClinicalTrials.gov
• Costs of biomarker testing in advanced non‐small cell lung cancer: a global study comparing next‐generation sequencing and single‐gene testing#155996HAL (France)
• Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen#160373ClinicalTrials.gov
• Development and validation of an MRI-based clinical-radiomics nomogram for predicting lymph node metastasis in non-small cell lung cancer.#220974NCBI PubMed Central
• Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial#311116ClinicalTrials.gov
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer#311140ClinicalTrials.gov
• Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC#366609ClinicalTrials.gov
• Frailty, initial attrition and the potential use of novel platinum-free options for non-small-cell lung cancer in the real-world setting#410898bioRxiv / medRxiv
• Metabolomic Characteristics of Patients With Non-Small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate: A Case-Control Study.#422944NCBI PubMed Central
• Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer.#433869NCBI PubMed Central
• Induction Lorlatinib in Stage III Non-small Cell Lung Cancer#804805ClinicalTrials.gov
• A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers#807301ClinicalTrials.gov
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors#839548ClinicalTrials.gov
• Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group#218144HAL (France)
• Early Palliative Care on Quality of Life of Advanced Cancer Patients#811391ClinicalTrials.gov
• Repurposing Bromhexine to Suppress Non-Small Cell Lung Cancer Growth by Inhibiting Methylenetetrahydrofolate dehydrogenase 2 - Dataset#196685Figshare
• Local Injection and Systemic Therapy in the Treatment of NSCLC.#824927ClinicalTrials.gov
• Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival#345886Springer Nature OA
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors#824951ClinicalTrials.gov
• Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study#11480HAL (France)
• Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC#141001ClinicalTrials.gov
• Explainable 1-mm Peritumoral CT Radiomics for EGFR Mutation Prediction in Non-small Cell Lung Cancer: A Vietnamese Real-World Cohort Study.#236072NCBI PubMed Central
• FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer.#322954NCBI PubMed Central
• Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter study.#334743NCBI PubMed Central
• Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers.#342464NCBI PubMed Central
• METTL3- and IGF2BP1-associated m6A regulation of FADS2 contributes to lipid droplet accumulation and malignant progression in non-small cell lung cancer.#368075NCBI PubMed Central